Combination drug strategy activates natural killer cell-mediated immunity to attack tumors

Most skin cancer drugs that activate the immune system work by triggering immune cells, called T cells, to attack tumors, but when T cells are activated for too long, they can wear out and cease to function.

Related Keywords

Australia ,Monash ,South Australia ,Gavin Robertson ,Arthur Berg ,Kishore Punnath ,Saketh Dinavahi ,Emily Henderson ,Nicholas Huntington ,Rajasekharan Somasundaram ,Meenhard Herlyn ,Momeneh Foroutan ,Cancer Immunology Research ,National Health ,Chocolate Tour Cancer Research Fund ,Monash University ,Penn State Cancer Institute ,Penn State College Of Medicine ,Foreman Foundation For Melanoma Research ,Research Council Of Australia ,Melanoma Research Alliance ,Astrazeneca ,Melanoma Research Foundation ,Wistar Institute ,Mike Geltrude Foundation ,Penn State College ,Murine Double Minute ,Penn State ,Yu Chi Chen ,Foreman Foundation ,Melanoma Research ,National Cancer Institute ,National Institutes ,Medical Research Council ,Cancer ,Fell ,Immunity ,Ermatology ,Drugs ,Exhaustion ,Immune System ,Mmunology ,Medicine ,Melanoma ,Melanoma Cells ,Natural Killer Cells ,Pathology ,Harmacology ,Research ,Skin ,Skin Cancer ,Surgery ,T Cell ,Humor ,